Extended Data Fig. 3: Pharmacodynamic effects of visugromab monotherapy in phase 1.
From: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
(a) Exhaustion markers PDCD1, HAVCR2 and LAG3 are not differentially expressed in pre-(baseline) (n = 6) and on-treatment (D14) (n = 5) biopsies following visugromab therapy in trial participants with >2-fold (IMM) and participants with <2-fold (NOIMM) increase in CD8+ and CD4+ T cells. Boxplots black line, median; red line, mean; box, IQR; ns, not significant, (P > 0.5 from two-sided Wilcoxon rank sum test). (b) Volcano plot presenting differentially expressed genes (NS = no significant change) in biopsies on day 14 of visugromab monotherapy compared to pre-treatment biopsies in participants with <2-fold (NOIMM) increase in CD8+ and CD4 + T cells. P values are from moderated t-test using limma.
